Barinthus Biotherapeutics plc 8-K/A, filed May 24, 2022
Barinthus Biotherapeutics plc. (BRNS)
About this 8-K/A
Barinthus Biotherapeutics plc filed this 8-K/A on May 24, 2022, reporting on events of May 12, 2022.
Items reported
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| Not Applicable | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trade Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.
EXPLANATORY NOTE
On May 13, 2022, Vaccitech plc (the “Company”) filed with the Securities and Exchange Commission (“SEC”) a Current Report on Form 8-K (“Original Form 8-K”) to disclose that it had dismissed BDO LLP (“BDO”) as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm. The Company provided BDO with a copy of the disclosures it made in the Original Form 8-K and requested that BDO furnish a letter addressed to the SEC stating whether it agrees with the statements made therein. This Form 8-K/A amends the Original Form 8-K solely to include a copy of BDO’s letter, dated May 20, 2022, which is filed as Exhibit 16.1 to this Form 8-K/A.
Except as described above, all other information in the Original 8-K remains unchanged.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| 16.1 | Letter from BDO LLP, dated May 20, 2022 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Vaccitech plc | ||
| Date: May 24, 2022 | By: |
/s/ William Enright |
| William Enright | ||
|
Chief Executive Officer | ||
Exhibit 16.1
 | Tel: +44 (0)20 7486 5888 Fax: +44 (0)20 7487 3686 DX 9025 West End W1 www.bdo.co.uk | 55 Baker Street London W1U 7EU |
May 20, 2022
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
United States of America
We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on May 10, 2022, filed by our former client, Vaccitech plc. We agree with the statements made in response to that Item insofar as they relate to our Firm.
Very truly yours,
/s/ BDO LLP
BDO LLP
BDO LLP, a UK limited liability partnership registered in England and Wales under number OC305127, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms. A list of members’ names is open to inspection at our registered office, 55 Baker Street, London W1U 7EU. BDO LLP is authorised and regulated by the Financial Conduct Authority to conduct investment business.